Weight-Loss Drugs Curb Drinking

Evidence from animal models and human observational studies suggests GLP‑1 receptor agonists like semaglutide reduce alcohol intake and relapse without simply sedating users. Target‑trial emulations report lower alcohol use among GLP‑1RA patients, and randomized trials appear imminent as drugmakers seek alcohol‑use‑disorder indications. If replicated, a drug taken for obesity could quietly cut population alcohol consumption. — A dual‑use therapy would reshape addiction policy, public‑health planning, and even sin‑tax and alcohol‑industry forecasts.